Community pharmacy is evolving to provide additional services to patients such as compliance improvement, selfcare and OTC consultations and advising on daily activities to supplement medical treatment. Currently in Japan, it has been estimated that 1.5 to 2 million people have chronic hepatitis C. We have attempted to increase the population's knowledge of this important issue with educational brochures about hepatitis C and placing posters encouraging them to ask medical professionals about their health problems. Peg-interferon and ribavirin combination therapy has an e‹cacy rate of approximately 60％. The side eŠects might present in diŠerent ways and frequency depending on the treatment duration; therefore, pharmacists should monitor patients carefully during the entire treatment period with particular attention to OTC drug use, daily activity, etc. Additionally, for outpatients community pharmacy has responsibility to avoid drug-related adverse events in the patients' daily life, so monitoring for clinical signs of side eŠects is necessary. We created the``Clinical Pathway for Healthcare Network of Chronic Hepatitis C Treatment via the Medication Notebook Type'' (Clinical Pathway) for patients who received Peg-interferon and ribavirin combination therapy. We are beginning to provide the new version of this service to patients as one of the pharmaceutical care components in the community pharmacy. I would like to describe how we cooperate with other community pharmacies using the``Clinical Pathway'', which is to improve patient care in the community pharmacies.
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